
-
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, August 8, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology…
-
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax’s multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG…
-
GeoVax to Participate in Upcoming Investor Conferences in September
Atlanta, GA, September 3, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today…
-
GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor Atlanta, GA, July 31, 2024…
-
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
GeoVax to Host Conference Call at 4:30 PM ET Atlanta, GA, July 30, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Company to discuss recent BARDA Project NextGen award for its next-generation COVID-19 vaccine and provide progress update across its clinical development pipeline …
-
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Atlanta, GA, July 11, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
GeoVax Provides First Half 2024 Business Update
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately…
-
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 Study is Funded by…
-
GeoVax to Present at BIO International Convention 2024
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® ATLANTA, GA, May 29, 2024 – GeoVax Labs, Inc.…
-
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA’s Clinical…
-
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
Atlanta, GA, May 17, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
